Rznomics Continues Joint Research with Lilly After Receiving Fourth Research Fee for Hearing-Loss Drug
Predicted impact: Low
Fourth research fee from Lilly is small relative to market value and revenue.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.